Suppr超能文献

眼内淋巴瘤:诊断与治疗的最新进展

Intraocular lymphoma: update on diagnosis and management.

作者信息

Chan Chi-Chao, Wallace Dana J

机构信息

Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

Cancer Control. 2004 Sep-Oct;11(5):285-95. doi: 10.1177/107327480401100502.

Abstract

BACKGROUND

Primary intraocular lymphoma (PIOL) is a subset of primary central nervous system lymphoma (PCNSL) in which lymphoma cells initially invade the retina, vitreous, or optic nerve head, with or without concomitant CNS involvement. The incidence of this previously rare condition has increased dramatically. Given its nonspecific presentation and aggressive course, PIOL provides a diagnostic and therapeutic challenge.

METHODS

We review the current strategies for diagnosis and treatment of PIOL and present our own experience with PIOL.

RESULTS

Recent developments in the diagnosis of PIOL include immunohistochemistry, flow cytometry, cytokine evaluation, and molecular analysis. However, definitive diagnosis still requires harvesting of tissue for histopathology. Optimal treatment for PIOL remains unclear. Initial therapeutic regimens should include methotrexate-based chemotherapy and radiotherapy to the brain and eye. In addition, promising results have been seen with intravitreal methotrexate and autologous stem cell transplantation for recurrent and refractory disease.

CONCLUSIONS

Efforts to further determine the immunophenotype and molecular characteristics of PIOL will continue to assist in the diagnosis of PIOL. Future studies are required to determine the role of radiotherapy and optimal local and systemic chemotherapeutic regimens.

摘要

背景

原发性眼内淋巴瘤(PIOL)是原发性中枢神经系统淋巴瘤(PCNSL)的一个亚型,其中淋巴瘤细胞最初侵犯视网膜、玻璃体或视神经乳头,伴或不伴有中枢神经系统受累。这种以前罕见的疾病的发病率已急剧上升。鉴于其非特异性表现和侵袭性病程,PIOL带来了诊断和治疗方面的挑战。

方法

我们回顾了PIOL的当前诊断和治疗策略,并介绍了我们自己治疗PIOL的经验。

结果

PIOL诊断方面的最新进展包括免疫组织化学、流式细胞术、细胞因子评估和分子分析。然而,明确诊断仍需要获取组织进行组织病理学检查。PIOL的最佳治疗方法仍不明确。初始治疗方案应包括以甲氨蝶呤为基础的化疗以及对脑部和眼部的放疗。此外,玻璃体内注射甲氨蝶呤和自体干细胞移植治疗复发和难治性疾病已取得了令人鼓舞的结果。

结论

进一步确定PIOL免疫表型和分子特征的努力将继续有助于PIOL的诊断。未来需要开展研究以确定放疗的作用以及最佳的局部和全身化疗方案。

相似文献

1
Intraocular lymphoma: update on diagnosis and management.
Cancer Control. 2004 Sep-Oct;11(5):285-95. doi: 10.1177/107327480401100502.
2
Management of primary intraocular lymphoma.
Curr Oncol Rep. 2005 Jan;7(1):74-9. doi: 10.1007/s11912-005-0029-6.
3
Diagnosis and management of primary intraocular lymphoma.
Hematol Oncol Clin North Am. 2005 Aug;19(4):739-49, viii. doi: 10.1016/j.hoc.2005.05.011.
4
[Primary intraocular lymphoma].
Ophthalmologe. 2004 Jan;101(1):87-98. doi: 10.1007/s00347-003-0855-6.
5
Ocular manifestations and treatment of central nervous system lymphomas.
Neurosurg Focus. 2006 Nov 15;21(5):E9. doi: 10.3171/foc.2006.21.5.10.
6
International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future.
Ocul Immunol Inflamm. 2006 Jun;14(3):139-44. doi: 10.1080/09273940600630170.
7
Intraocular lymphoma.
Curr Opin Ophthalmol. 2002 Dec;13(6):411-8. doi: 10.1097/00055735-200212000-00012.
8
Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features.
Graefes Arch Clin Exp Ophthalmol. 2004 Nov;242(11):901-13. doi: 10.1007/s00417-004-0973-0. Epub 2004 Oct 29.
10
Ocular manifestations of central nervous system lymphoma.
Curr Opin Oncol. 2001 May;13(3):137-42. doi: 10.1097/00001622-200105000-00001.

引用本文的文献

1
Next-gen oncology: the role of CAR-T cells against ocular lymphoma and myeloma.
Eye (Lond). 2024 Dec;38(18):3416-3417. doi: 10.1038/s41433-024-03324-6. Epub 2024 Sep 12.
2
Ophthalmic Manifestations in Patients with Blood Malignancies.
Hematol Rep. 2024 Mar 28;16(2):193-203. doi: 10.3390/hematolrep16020020.
3
Unilateral panuveitis secondary to mutation-associated lymphoproliferative disease.
BMJ Case Rep. 2022 Dec 5;15(12):e253572. doi: 10.1136/bcr-2022-253572.
4
Update in Molecular Testing for Intraocular Lymphoma.
Cancers (Basel). 2022 Sep 20;14(19):4546. doi: 10.3390/cancers14194546.
5
Refractory Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete Response to Tirabrutinib.
Intern Med. 2023 Feb 1;62(3):459-463. doi: 10.2169/internalmedicine.9591-22. Epub 2022 Jul 5.
7
Clinical Outcomes in Vitrectomized versus Non-vitrectomized Eyes in Patients with Primary Vitreoretinal Lymphoma.
Ocul Immunol Inflamm. 2023 Apr;31(3):496-500. doi: 10.1080/09273948.2022.2033794. Epub 2022 Feb 24.
9
Advanced OCT Analysis of Biopsy-proven Vitreoretinal Lymphoma.
Am J Ophthalmol. 2022 Jun;238:16-26. doi: 10.1016/j.ajo.2021.11.023. Epub 2021 Nov 27.
10
Challenges in the Diagnosis of Intraocular Lymphoma.
Turk J Ophthalmol. 2021 Oct 26;51(5):317-325. doi: 10.4274/tjo.galenos.2021.50607.

本文引用的文献

1
Molecular pathology of primary intraocular lymphoma.
Trans Am Ophthalmol Soc. 2003;101:275-92.
5
Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnosis of primary intraocular lymphoma in patients with Masquerade syndrome.
Graefes Arch Clin Exp Ophthalmol. 2003 Oct;241(10):860-70. doi: 10.1007/s00417-003-0749-y. Epub 2003 Sep 30.
6
Clinical use of rituximab in haematological malignancies.
Br J Cancer. 2003 Oct 20;89(8):1389-94. doi: 10.1038/sj.bjc.6601187.
8
Vitreous cytokine levels.
Ophthalmology. 2003 Aug;110(8):1671-2. doi: 10.1016/S0161-6420(03)00811-X.
9
Rituximab for follicular lymphoma.
Curr Hematol Rep. 2003 Jan;2(1):13-22.
10
Primary ocular lymphoma: clinical features, diagnosis, and treatment.
Clin Lymphoma. 2003 Jun;4(1):22-9. doi: 10.3816/clm.2003.n.010.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验